Utama › Kanser Metastatik › Illinois › Chicago
Kajian klinikal Kanser Metastatik di Chicago, IL
45 kajian untuk Kanser Metastatik sedang mencari peserta di lokasi dalam dan sekitar Chicago (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Mengambil pesertaFasa 3
- City of Hope, Chicago
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Mengambil pesertaFasa 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- dan 3 lagi
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Mengambil pesertaFasa 1
- Northwestern University, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Mengambil pesertaFasa 1
- University of Chicago Hospital, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Mengambil pesertaFasa 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Mengambil pesertaFasa 3
- Illinois Cancer Specialists, Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Mengambil pesertaFasa 3
- Research Site, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Mengambil pesertaFasa 1/2
- University of Chicago, Chicago
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Mengambil pesertaFasa 3
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medicine, Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Mengambil pesertaFasa 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Mengambil pesertaFasa 3
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago
CREO - Microwave Ablation Feasibility Study
Mengambil peserta
- Rush University Medical Center, Chicago
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Mengambil pesertaFasa 1
- Northwestern University ( Site 0101), Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Mengambil pesertaFasa 2
- Northwestern University, Chicago
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Mengambil pesertaFasa 3
- Northwestern University, Chicago
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Mengambil pesertaFasa 1/2
- Northwestern University, Chicago
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Mengambil pesertaFasa 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Mengambil pesertaFasa 2
- Research Site, Chicago
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Mengambil pesertaFasa 1
- University of Chicago Comprehensive Cancer Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Mengambil pesertaFasa 3
- Research Site, Chicago
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- The University of Chicago Medicine, Chicago
A Study of PYX-201 in Advanced Solid Tumors
Mengambil pesertaFasa 1
- University of Chicago Medicine, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Mengambil pesertaFasa 1
- The University of Chicago Medical Center (UCMC), Chicago
REMASTer: REcurrent Brain Metastases After SRS Trial
Mengambil peserta
- University of Chicago, Chicago
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Mengambil pesertaFasa 3
- Northwestern University, Chicago
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Mengambil pesertaFasa 2
- Northwestern University, Chicago
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Mengambil pesertaFasa 1
- Context Investigational Site, Chicago
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Mengambil pesertaFasa 1/2
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Mengambil pesertaFasa 1/2
- University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 3
- University of Illinois Cancer Center, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Mengambil pesertaFasa 2/3
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Mengambil pesertaFasa 1
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Mengambil pesertaKajian pemerhatian
- John H Stroger Jr Hospital of Cook County, Chicago
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Mengambil pesertaFasa 1
- University of Illinois at Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Mengambil pesertaFasa 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Mengambil pesertaFasa 3
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Mengambil pesertaFasa 1
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Chicago
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Mengambil pesertaFasa 1
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Mengambil pesertaFasa 1
- Northwestern University, Chicago
- University of Illinois, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Mengambil pesertaFasa 1
- University of Chicago, Chicago
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Northwestern University, Chicago
Kajian Kanser Metastatik di bandar lain
- Houston, TX104 kajian
- New York City, NY93 kajian
- Nashville, TN70 kajian
- Boston, MA63 kajian
- Los Angeles, CA57 kajian
- St. Louis, MO54 kajian
- Arlington, VA53 kajian
- Philadelphia, PA46 kajian
- San Antonio, TX44 kajian
- Washington, DC43 kajian
- Dallas, TX42 kajian
- Seattle, WA39 kajian
Kajian lain di Chicago
- Kanser Paru-paru Bukan Sel Kecil61 kajian
- Kanser Payudara59 kajian
- Kanser (semua jenis)51 kajian
- Kanser Prostat45 kajian
- Kanser Paru-paru41 kajian
- Obesiti41 kajian
- Kanser Ovari36 kajian
- Kanser Kolorektal34 kajian
- Strok34 kajian
- Kegagalan Jantung31 kajian
- Berat Badan Berlebihan29 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher26 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.